Menu
Search
|

Menu

Close
X

Adverum Biotechnologies Inc ADVM.OQ (NASDAQ Stock Exchange Global Market)

6.62 USD
-0.17 (-2.57%)
As of 11:44 AM EST
chart
Previous Close 6.80
Open 6.80
Volume 75,235
3m Avg Volume 142,840
Today’s High 7.10
Today’s Low 6.60
52 Week High 8.55
52 Week Low 2.45
Shares Outstanding (mil) 45.04
Market Capitalization (mil) 306.28
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
1
FY16
1
FY15
2
EPS (USD)
FY17
-0.967
FY16
-3.208
FY15
-1.859
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.59
Price to Sales (TTM)
vs sector
163.26
8.08
Price to Book (MRQ)
vs sector
1.63
5.24
Price to Cash Flow (TTM)
vs sector
--
25.98
Total Debt to Equity (MRQ)
vs sector
0.00
15.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.18
Return on Investment (TTM)
vs sector
-29.34
13.67
Return on Equity (TTM)
vs sector
-30.56
15.40

EXECUTIVE LEADERSHIP

Paul Cleveland
Chairman of the Board, Since 2017
Salary: $504,000.00
Bonus: --
Amber Salzman
Chief Executive Officer, Principal Executive Officer, Director, Since 2017
Salary: $312,500.00
Bonus: --
Leone Patterson
Chief Financial Officer, Since 2016
Salary: --
Bonus: --
Athena Countouriotis
Senior Vice President, Chief Medical Officer, Since 2017
Salary: --
Bonus: --
Mehdi Gasmi
Chief Science and Technology Officer, Since 2016
Salary: $385,000.00
Bonus: $103,333.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1035 Obrien Dr
MENLO PARK   CA   94025-1408

Phone: +1650.2726269
Site: adverum.com/

Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing gene therapeutics for ophthalmic diseases. It is focused on developing gene therapy programs to address unmet medical needs of diseases, such as wet age-related macular degeneration (wAMD), alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE). The Company's principal product pipeline includes ADVM-022/032 for the treatment of wAMD, and ADVM-043 and ADVM-053 for the treatment of A1AT and HAE respectively. The ADVM-22 and ADVM-032 are anti- vascular endothelial growth factor (VEGF) gene therapy candidates administered intra-viterally. ADVM-043 induces long-term A1AT protein levels with a single intravenous administration. Through the partnership programs with Editas Medicine, Inc. and Regeneron Pharmaceuticals, Inc., the Company develops gene therapies for inherited retinal and ocular diseases.

SPONSORED STORIES